Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer


Data + Perspectives: Clinical Investigators Explore the Current and Future Management of Triple-Negative Breast Cancer
Proceedings from a satellite symposium during the 42nd annual San Antonio Breast Cancer Symposium. Featuring perspectives from Dr Erika Hamilton, Prof Sherene Loi, Dr Mark E Robson and Dr Hope S Rugo.
2 AMA PRA Category 1 Credits™
To complete the Post-test and Educational Assessment and Credit Form, click here. A statement of CME credit will be issued for scores of 80% or better. Your statement of credit will be mailed to you within 3 weeks or may be printed online.

Introduction

Established Management Paradigms for Advanced Triple-Negative Breast Cancer (TNBC); Actionable and Other Potentially Relevant Biomarkers to Inform Decision-Making

Immune Checkpoint Inhibition as a Rational Therapeutic Strategy for Advanced TNBC

Available Data with and Practical Integration of PARP Inhibition into the Care of Patients with mTNBC

Novel Applications of Immune Checkpoint Inhibitors Alone or in Combination with Other Agents for Patients with Early and Advanced TNBC; Other Promising Agents in Late-Stage Clinical Trials